Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Psilocybin · COMP-360, PEX010

Small molecule · Agonist of serotonin 2A receptor (HTR2A) · developed by COMPASS Pathways

Phase 3 Most advanced trial

CMPS Developer

4 Registered trials

What is Psilocybin?

Psilocybin is a tryptamine alkaloid from fungi that is rapidly dephosphorylated to psilocin, which activates serotonin 2A receptors in the central nervous system. It is being studied for treatment-resistant depression and major depressive disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: COMP-360, PEX010, CY-39, Psilocibin
Drug type: Small molecule
Targets: serotonin 2A receptor (HTR2A)
Mechanism: Agonist of serotonin 2A receptor (HTR2A)
Pathways: serotonin signaling
Therapy area: Psychiatry
Developer: COMPASS Pathways (CMPS, CMPX)
Also in trials of: CRL, HELP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 2RV7212BP0

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05711940	Phase 3	Treatment Resistant Depression	Active not recruiting	CMPS
NCT06512194	Phase 2	Depression	Recruiting	CRL
NCT05594667	Phase 2	Depression	Withdrawn	HELP
NCT07719088	Phase 1	Aging	Not yet recruiting	CRL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AgingBiomarkers of AgingLongevityTreatment Resistant DepressionDepressionDepressive DisorderMajor Depressive DisorderMild DepressionModerate Depression

Other drugs acting on HTR2A

Aripiprazole Lauroxil FDA approved Asenapine FDA approved Iloperidone FDA approved Milsaperidone FDA approved Pimavanserin FDA approved

More from COMPASS Pathways

COMP360 psilocybin Phase 2/3 CTX-10726 Phase 1 CTX-471 Phase 1/2 CTX-8371 Phase 1 Tovecimig Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.

Follow CMPS, the company behind Psilocybin

See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMPS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z